# SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis

> **NCT03783416** · PHASE1 · RECRUITING · sponsor: **Queen Mary University of London** · enrollment: 72 (estimated)

## Conditions studied

- Relapsing Remitting Multiple Sclerosis
- Primary Progressive Multiple Sclerosis
- Secondary Progressive Multiple Sclerosis

## Interventions

- **DRUG:** Ixazomib (NINLARO®) capsules / Matching placebo capsules

## Key facts

- **NCT ID:** NCT03783416
- **Lead sponsor:** Queen Mary University of London
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-06-15
- **Primary completion:** 2026-07-31
- **Final completion:** 2026-07-31
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2025-09-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03783416

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03783416, "SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03783416. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*